维普中文期刊产品整合服务
25篇 您的检索式:作者名="Thomas IM"
    题名 作者 年代 出处 被引量
1Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial显示文摘Aimery de Gramont Eric Van Cutsem Hans-Joachim Schmoll Josep Tabernero Stephen Clarke Malcolm J Moore David Cunningham Thomas H Cartwright J Randolph Hecht Fernando Rivera Seock-Ah Im Gy?rgy Bodoky Ramon Salazar Frédérique Maindrault-Goebel Einat Shacham- 2012Lancet Oncology2012,,12:3
2Prooaostie factors inadvanced synovial sarcoma:an analysis of 104 patients treated at theRoyal Marsden Hospital显示文摘Spurrell EI Fisher C Thomas IM 0,,03:1
3Sacroiliitis in patients with ankylosing spondylitis: association of MR findings with disease activity显示文摘Won-Hee Jee Thomas R. McCauley Sang-Heon Lee Sung-Hoon Kim Soo-Ah Im Kee-Yong Ha 2004Magnetic Resonance Imaging2004,,2:1
4The importance of folate, zinc and antioxidants in the pathogenesis and prevention of subfertility显示文摘Ebisch IM Thomas CM Peters WH 2007Hum Reprod Update2007,13,:1
5Hom0cysteine, glutathione and related thiols affect fertility parameters in the (sub) fertile couple显示文摘Ebisch IM Peters WH Thomas CM 2006Hum Reprod2006,21,:1
6The importance of folate,zinc and antioxidants in the pathogenesis and prevention of subfertility显示文摘Ebisch IM Thomas CM Peters WH Human Reproduction0,,:1
7C677T methylenete- trahydrofolate reductase polymorphism interferes with the effects of folic acid and zinc sulftate on sperm concentration 显示文摘Ebisch IM van Heerde WL Thomas CM 2003Fertil Steril2003,80,:1
8Population dynamics of arterial smooth muscle cells: cells proliferation and cell death during initial 3 months in atherosclerosis lesions induced in swine by hypercholesterolemic diet and initial trauma显示文摘Thomas WA Reiner IM Flormin FA Lee KT Lee WM 1976Exp Mol Pathol1976,24,:1
9High Laser Damage Thresholds Porous Silica Antireflective Coating显示文摘 1986Appl Opt1986,25,:1
10The importmace of hemoglobin levels durging radiotherapy for carcinoma of the cervix显示文摘GROGAN IM THOMAS G M MELAMED I 1999Cancer1999,86,8:1
11The importance of fo- late, zinc and antioxidants in the pathogenesis and prevention of subfertility 显示文摘Ebisch IM Thomas CM Peters WH 2007Hum Reprod Update2007,13,2:1
12High Laser Damage Threshold Porous Silica Antireflective Coating显示文摘Thomas IM 1986Applied Optics1986,25,9:1
13Heterochronic parabiosis:historical perspective and methodological considerations for studies of aging and longevity显示文摘Conboy MJ Conboy IM Thomas A 2013Aging Cell2013,12,10:1
14Heterochronic parabiosis:historical perspective and methodological considerations for studies of aging and longevity显示文摘Conboy MJ Conboy IM Thomas A 2013Aging Cell2013,12,10:1
15Hepatic decompensation/serious adverse events in post-liver transplantation recipients on sofosbuvir for recurrent hepatitis C virus显示文摘AIM: To determine the safety profile of new hepatitis C virus(HCV) treatments in liver transplant(LT) recipients with recurrent HCV infection.METHODS: Forty-two patients were identified with recurrent HCV infection that underwent LT at least 12 mo prior to initiating treatment with a Sofosbuvir-based regimen during December 2013-June 2014. Cases were patients who experienced hepatic decompensation and/or serious adverse events(SAE) during or within one month of completing treatment. Controls had no evidence of hepatic decompensation and/or SAE. HIVinfected patients were excluded. Cumulative incidence of decompensation/SAE was calculated using the Kaplan Meier method. Exact logistic regression analysis was used to identify factors associated with the composite outcome. RESULTS: Median age of the 42 patients was 60 years [Interquartile Range(IQR): 56-65 years], 33%(14/42) were female, 21%(9/42) were Hispanic, and 9%(4/42) were Black. The median time from transplant to treatment initiation was 5.4 years(IQR: 2.1-8.8 years). Thirteen patients experienced one or more episodes of hepatic decompensation and/or SAE. Anemia requiring transfusion, the most common event, occurred in 62%(8/13) patients, while 54%(7/13) decompensated. The cumulative incidence of hepatic decompensation/SAE was 31%(95%CI: 16%-41%). Risk factors for decompensation/SAE included lower pre-treatment hemoglobin(OR = 0.61 per g/d L, 95%CI: 0.40-0.88, P < 0.01), estimated glomerular filtration rate(OR = 0.95 per m L/min per 1.73 m^2, 95%CI: 0.90-0.99, P = 0.01), and higher baseline serum total bilirubin(OR = 2.43 per mg/d L, 95%CI: 1.17-8.65, P < 0.01). The sustained virological response rate for the cohort of 42 patients was 45%, while it was 31% for cases.CONCLUSION: Sofosbuvir/ribavirin will continue to be used in the post-transplant population, including those with HCV genotypes 2 and 3. Management of anemia remains an important clinical challenge.Neal Patel Kian Bichoupan Lawrence Ku Rachana Yalamanchili Alyson Harty Donald Gardenier Michel Ng David Motamed Viktoriya Khaitova Nancy Bach Charissa Chang Priya Grewal Meena Bansal Ritu Agarwal Lawrence Liu Gene Im Jennifer Leong Leona Kim-Schluger Joseph Odin Jawad Ahmad Scott Friedman Douglas Dieterich Thomas Schiano Ponni Perumalswami Andrea Branch 2016World Journal of Gastroenterology2016,22,9:1
16The importance of folate,zinc and antioxidants in the pathogenesis and prevention of subfertility显示文摘Ebisch IM Thomas CM Peters WH 2007Hum Reprod Update2007,13,2:1
17Real-world cure rates for hepatitis C virus treatments that include simeprevir and/or sofosbuvir are comparable to clinical trial results显示文摘AIM To assess the real-world effectiveness and cost of simeprevir(SMV), and/or sofosbuvir(SOF)-based therapy for chronic hepatitis C virus(HCV) infection.METHODS The real-world performance of patients treated with SMV/SOF ± ribavirin(RBV), SOF/RBV, and SOF/RBV with pegylated-interferon(PEG) were analyzed in a consecutive series of 508 patients with chronic HCV infection treated at a single academic medical center. Patients with genotypes 1 through 4 were included. Rates of sustained virological response-the absence of a detectable serum HCV RNA 12 wk after the end of treatment [sustained virological response(SVR) 12]-were calculated on an intention-to-treat basis. Costs were calculated from the payer's perspective using Medicare/Medicaid fees and Redbook Wholesale Acquisition Costs. Patient-related factors associated with SVR12 were identified using multivariable logistic regression.RESULTS SVR 12 rates were as follows: 86%(95%CI: 80%-91%)among 178 patients on SMV/SOF ± RBV; 62%(95%CI: 55%-68%) among 234 patients on SOF/RBV; and 78%(95%CI: 68%-86%) among 96 patients on SOF/PEG/RBV. Mean costs-per-SVR 12 were $174442(standard deviation: ± $18588) for SMV/SOF ± RBV; $223003(± $77946) for SOF/RBV; and $126496(± $31052) for SOF/PEG/RBV. Among patients on SMV/SOF ± RBV, SVR12 was less likely in patients previously treated with a protease inhibitor [odds ratio(OR): 0.20, 95%CI: 0.06-0.56]. Higher bilirubin(OR: 0.47, 95%CI: 0.30-0.69) reduced the likelihood of SVR12 among patients on SOF/RBV, while FIB-4 score ≥ 3.25 reduced the likelihood of SVR 12(OR: 0.18, 95%CI: 0.05-0.59) among those on SOF/PEG/RBV. CONCLUSION SVR 12 rates for SMV and/or SOF-based regimens in a diverse real-world population are comparable to those in clinical trials. Treatment failure accounts for 27% of costs.Kian Bichoupan Neeta Tandon James F Crismale Joshua Hartman David Del Bello Neal Patel Sweta Chekuri Alyson Harty Michel Ng Keith M Sigel Meena B Bansal Priya Grewal Charissa Y Chang Jennifer Leong Gene Y Im Lawrence U Liu Joseph A Odin Nancy Bach Scott L Friedman Thomas D Schiano Ponni V Perumalswami Douglas T Dieterich Andrea D Branch 2017World Journal of Virology2017,6,4:1
18Daily limited access to sweetened drink attenuates hypothalamic-pituitary-adrenocortical axis stress responses显示文摘Ulrich-Lai YM Ostrander MM Thomas IM 2007Endocr inology2007,148,:1
19Population dynamics of arterial smooth muscle cells:V, cells proliferation and cell death during initial 3 mouths in atherosclerosis lesions induced in swine by hypercholesterolemic diet and initial trauma显示文摘Thomas WA Reiuer IM Flormin FA 1976Exp Mol Pathol1976,24,:1
20Homocysteine,glutathione and related thiols affect fertility parameters in the (sub)fertile couple显示文摘Ebisch IM Peters WH Thomas CM 2006Hum Reprod2006,21,7:1
返回顶部 每页显示:
共2页 首页 上一页 第1页 下一页 末页 /2 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费